



CERTIFICATE FROM IP CONSULTANT

Date: 08.07.2025

To,

The Board of Directors
Anthem Biosciences [Private] Limited
 NO. 49, F1 & F2, Canara Bank Road
 Bommasandra Industrial Area
 Phase 1, Bommasandra, Bangalore
 Karnataka, India, 560 099

JM Financial Ltd.
 7th Floor, Cnergy
 Appasaheb Marathe Marg
 Prabhadevi, Mumbai 400 025
 Maharashtra, India

Citigroup Global Markets India Private Limited
 12th Floor, First International Financial Center,
 G-Block Bandra Kurla Complex, Bandra (East),
 Mumbai – 400 098
 Maharashtra, India
 Tel: +91 22 6175 9999

J.P. Morgan India Private Limited
 J.P. Morgan
 6F, J.P. Morgan Towers
 Off. C.S.T. Road, Kalina
 Santacruz - East, Mumbai - 400 098
 Tel: +91 22 6157 3000

Nomura Financial Advisory and Securities (India) Private Limited
 Ceejay House, Level 11,
 Plot F Shiv Sagar Estate,
 Dr. Annie Besant Marg,
 Worli Mumbai – 400 018 Tel: +91 22 4037 4037

JM Financial Ltd., Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited, Nomura Financial Advisory and Securities (India) Private Limited and any other book running lead managers which may be appointed in relation to the Offer are collectively referred to as the “Book Running Lead Managers” or the “BRLMs”)

Re: Proposed initial public offering of equity shares (the “Equity Shares”) of Anthem Biosciences [Private] Limited (the “Company”) comprising an offer for sale of the Equity Shares by certain existing shareholders of the Company (“Offer for Sale” or the “Offer”)

Kolkata
 Martin Burn, Business Park
 Sector 4 901, BP Block, Sector V
 Salt Lake, Kolkata 700 091, India
 p: +91 33 4055 1111
 f: +91 33 4055 1112
 e: cal@patentindia.com

New Delhi
 D-14 Lajpat Nagar III
 Ground Floor
 New Delhi 110 024, India
 p: +91 11 4610 8738 / 4109 7455
 f: +91 11 4109 7456
 e: del@patentindia.com

Mumbai
 202 Electron Chambers
 Behnd Saki Naka Tel Exchange
 Mumbai 400 072, India
 p: +91 22 2852 2901 / 2902
 f: +91 22 2852 2903
 e: bom@patentindia.com



In connection with the Offer, S Majumdar & Co (“we” or “us”) have been requested by the Company to examine, verify, certify and confirm certain details in relation to registered trademarks, patents, and applications for registration of trademarks and patents of the Company and its subsidiary, namely Neoanthem Lifesciences Private Limited (“Subsidiary”), whether owned, licensed or otherwise used by the Company or the Subsidiary, identified in [Annexures A and B hereto], and for inclusion of the information contained in this report and the annexures (in part or full), including any extracts thereof, in the Draft Red Herring Prospectus (“DRHP”) intended to be filed with the Securities and Exchange Board of India (“SEBI”), the BSE Limited (the “BSE”) and the National Stock Exchange of India Limited (“NSE” and together with the BSE, the “Stock Exchanges”), the red herring prospectus (“RHP”) and the prospectus (“Prospectus”), which the Company intends to file with the Registrar of Companies, Karnataka at Bengaluru (“RoC”) and thereafter file with the SEBI and the Stock Exchanges and in any other Offer-related documents, including any addenda or supplements thereto (“Offer Documents”) and in roadshow or investor presentations, research reports, and any other marketing and/or publicity material related to the Offer (together with the Offer Documents, the “Offer Materials”).

I. IPR FILINGS AND REGISTRATIONS:

Pursuant to the engagement letter dated 19th of August 2024, the Company has engaged our services to examine, verify, certify and confirm the details of the intellectual property of the Company and its Subsidiary in India and overseas, including but not limited to trademarks and patents, whether owned, or otherwise used by the Company and its Subsidiary, as of date 31.03.2025, enclosed in Annexures A and B. We have been provided access to the list of registered trademarks and patents, the list of sources and country-wise. We have reviewed the trademark and patent registrations and applications of the Company and its Subsidiary, as amended from time-to-time which are available on the official website of Office of the Controller General of Patents, Designs and Trademarks, Department for Promotion of Industry and Internal Trade, Ministry of Commerce and Industry, Government of India and respective patent and Trade Mark Offices. We have ourselves visited the aforesaid website and have gone through/downloaded and viewed critically the following trademarks and patents which have been granted to the Company and its Subsidiary. Upon reviewing such registrations and certificates thereof, we confirm the records for the following trademarks and patents granted to the Company and its Subsidiary.

TRADEMARKS:

A. Company

India

As of 31.03.2025, the Company has 14 trade mark applications, out of which 7 are registered, and 7 are pending before the Trade Marks Registry. Two trade mark applications are opposed by different parties, and two trade mark applications are objected by the Trade Marks Registry.

The registered Trade Mark Nos. 4988829, 5016396, 5833849, 5833851, 5833852 fall in Class 5 while registered Trade Mark No. 5252039 cover Class 5, 29 and 43 and registered Trade Mark No. 4584678 fall in Class 44.

B. Neoanthem Lifesciences Private Limited

India

As of 31.03.2025, the Company has 3 trade mark applications, all of which are pending before the Trade Marks Registry. Two trade mark applications are opposed by Anthem Inc., and one trade mark application is objected by the Trade Marks Registry.

All the details of trademarks enclosed at Annexure A.



PATENTS:

A. Company

India

As of 31.03.2025, the Company has 8 published and subsisting applications, of which 7 are pending before the Patent Office, and 1 is granted.

Overseas Jurisdiction

As of 31.03.2025, the Company has 17 published and subsisting applications, of which 7 are granted, and 10 are pending before respective Patent Offices.

All the details of patents enclosed at **Annexure B**.

We hereby confirm that we are an independent consultant, with no direct or indirect interest in, or connected with or related to the Company, its Subsidiary, its group companies, promoters, members of promoter group, directors, shareholders, officers, employees, agents and representatives of the Company, the BRLMs or their affiliates and that no such party is a 'related party' in relation to me/us in terms of the Companies Act, 2013 read with rules notified thereunder, each as amended ("Companies Act"), or the applicable accounting standards under applicable law, and that no circumstance subsists that would materially impact my /our confirmations and findings as expressed in this report. Further, we are not interested in the formation, promotion, or management of the Company.

We hereby consent to be named as an 'expert' under Section 2(38) read with Section 26(5) of the Companies Act, and any other applicable provisions of the Companies Act or under any other applicable law, and the consents of and references to this report being reproduced and/or under in any documents, representations, releases, presentations, publicity material or other material prepared by or on behalf of or in relation to the Company, as may be considered necessary, including any Offer Documents, memoranda or other documents, by whatever name called, prepared in connection with the Offer, including being made available for inspection in relation to the Offer.

The following information in relation to me / us may be disclosed in the Offer Documents:

Name: S Majumdar & Co

Address: 5, Harish Mukherjee Road, Kolkata - 700 025 West Bengal

Telephone Number: + 91 33 2455 7484/85/86

E-mail: cal@patentindia.com

We confirm that we shall immediately communicate any changes in writing to the above information to the Company, the BRLMs and the legal advisors to each of the Company and the BRLMs until the date when the Equity Shares in the Offer are listed and commence trading on the Stock Exchanges. In the absence of any such communication from me/us, the BRLMs and the legal advisors to each of the Company and the BRLMs can assume that there is no change to the above information.

We hereby confirm that all the information and statements set forth in Annexures A **and** are true, fair, correct, accurate, not misleading and without omission of any matter that is likely to mislead. We further confirm that we are qualified to issue this certification.

This report (including the annexures hereto) can be relied upon by the BRLMs and the legal advisors to each of the Company and BRLMs appointed in relation to the Offer. This report may be delivered or furnished to SEBI, the Stock Exchanges or any governmental or regulatory authority, as may be required and for the purpose of



S MAJUMDAR & CO

Advocates, Patent & Trademark Attorneys

Kolkata | New Delhi | Mumbai

www.majumdarip.com

any defense that the BRLMs may wish to advance in any claim or proceedings in connection with the contents of this report or its contents included in the Offer Documents.

We also consent to the inclusion of this certificate (including the annexures hereto) as a part of "*Material Contracts and Documents for Inspection*" in connection with this Offer, which will be available for public for inspection from date of the filing of the RHP until the Bid/ Offer Closing Date.

We hereby authorize you to deliver this certificate to SEBI (including for any inspections), the Stock Exchanges, the RoC and/or any other governmental, regulatory, judicial, or statutory authority and/or for any other litigation purposes and/or for the records to be maintained by the BRLMs and in accordance with applicable law. We hereby consent to this certificate being disclosed by the Book Running Lead Managers, if required (i) by reason of any law, regulation or order of a court or by any government or competent regulatory authority, or (ii) in seeking to establish a defense in connection with, or to avoid, any actual, potential or threatened legal, arbitral or regulatory proceeding or investigation.

All capitalized terms used herein, unless otherwise specifically defined, shall have the same meaning as ascribed to them in the [DRHP/RHP/Prospectus].

We agree to keep information regarding the Offer strictly confidential.

Yours sincerely,

For and on behalf of S Majumdar & Co,

Amrita Majumdar

Authorized signatory

Name: Amrita Majumdar, Partner

Encl.: As above

CC:

Cyril Amarchand Mangaldas
3rd Floor, Prestige Falcon Towers
19, Brunton Road
Off M.G. Road, Bengaluru 560 025
Karnataka, India

White & Case Pte. Ltd.
88 Market Street
Capita Spring, #41-01
Singapore 048948

Trilegal
One World Center, Tower 2A and 2B
10th floor, Senapati Bapat Marg
Lower Parel West
Mumbai, Maharashtra 400013



Annexure A

DETAILS OF THE TRADEMARKS

Annexure A1

Company

Sl. No.	Trade Mark	Jurisdiction	Status (Whether registered or Not)	Registration No / Application No	Date of Registration / Application	Class	Renewed up to date	Remarks
1.	ANTHEM BIOSCIENCES	India	Registered	4988829	31/05/2021	5	31/05/2031	
2.	TRANS K27	India	Registered	5016396	23/06/2021	5	23/06/2031	
3.	INKULT	India	Registered	5252039	18/12/2021	5, 29, 43	18/12/2031	
4.	ANPROZYME	India	Registered	5833849	03/03/2023	5	03/03/2033	
5.	ASEPTIDASE	India	Pending, Not yet registered	5833850	03/03/2023	5	Not applicable	Objected by the Trademark Registry
6.	AFLAMASE	India	Registered	5833851	03/03/2023	5	03/03/2033	
7.	ANTHOPEPTID ASE	India	Registered	5833852	03/03/2023	5	03/03/2033	
8.	BACILLUS CLAUSII ACC0079	India	Pending, Not yet registered	6045079	31/07/2023	5	Not applicable	Objected by the Trademark Registry
9.	ANTHOFOL	India	Pending, Not yet registered	6582477	20/08/2024	5	Not applicable	
10.	POLINOFOL	India	Pending, Not yet registered	6582496	20/08/2024	5	Not applicable	
11.	FOLATHEM	India	Pending, Not yet registered	6582594	20/08/2024	5	Not applicable	
12.		India	Pending, Not yet registered	4584673	28/07/2020	5	Not applicable	Opposed by (1) Urmila Singh claiming to be trading as Anthemyv



									et Pharma, and (2) Amrendr a Nath Rai claiming to be trading as Anthem Healthca re
13.		India	Pending, Not yet registered	4584676	28/07/2020	42	Not applicable	Opposed by Anthem Inc.	
14.		India	Registered	4584678	28/07/2020	44	28/07/2030		

Annexure A2

Neoanthem Lifesciences Private Limited

Sl. No.	Trade Mark	Jurisdiction	Status (Whether registered or Not)	Registration No / Application No	Date Of Registration / Application	Class	Renewed up to date	Remarks
1.	NEOANTHEM	India	Pending, Not yet registered	5039698	10/07/2021	5	Not applicable	Opposed by Anthem Inc.
2.	NEOANTHEM	India	Pending, Not yet registered	5039699	10/07/2021	42	Not applicable	Opposed by Anthem Inc.
3.	NEUTROGRAS TIM	India	Pending, Not yet registered	5378430	21/03/2022	5	Not applicable	Objected by the Trademark Registry



Annexure B

DETAILS OF THE PATENTS

Annexure B1

Company

Indian Patents

Sl. No.	Title of the Patent	Jurisdiction	Status (Whether registered or Not)	Registration No / Application No	Date Of Application	Estimated Expiry date	Remarks
1.	SYNTHESIS OF A GUANYLATE CYCLASE AGONIST BY FRAGMENTS BASED APPROACH.	India	Applied	IN202041025485A	17-Jun-2020	17-Jun-2040	
2.	PROCESS OF PREPARATION OF GUANYLATE CYCLASE 2C AGONIST	India	Granted	IN202041036855A	27-Aug-2020	27-Aug-2040	
3.	A CONTINUOUS FLOW PROCESS FOR PREPARING SULPHOBUTYL ETHER CYCLODEXTRIN	India	Applied	IN202141034236A	29-Jul-2021	29-Jul-2041	
4.	SYNTHESIS OF GLP-1 ANALOGUES	India	Applied	IN202141057459A	10-Dec-2021	10-Dec-2041	
5.	PROCESS FOR THE PREPARATION OF β -D-GALACTOSAMINE, α -D-GALACTOSAMINE AND SALTS THEREOF	India	Applied	IN202141061648A	30-Dec-2021	30-Dec-2041	
6.	PROCESS FOR PREPARATION OF VITAMIN K2 FROM PRENYL KETONES	India	Applied	IN202241010343A	25-Feb-2022	25-Feb-2042	
7.	PROCESS FOR THE PREPARATION OF CHOLESTEROL FROM BISNORALCOHOL	India	Applied	IN202241069696A	2-Dec-2022	2-Dec-2042	
8.	SYNTHESIS OF GLUCAGON-LIKE PEPTIDE-1 ANALOGUES	India	Applied	IN202341031543A	3-May-2023	3-May-2043	



Overseas Patents

Sl. No.	Title of the Patent	Jurisdiction	Status (Whether registered or Not)	Registration No / Application No	Date Of Application	Estimated Expiry date	Remarks
1.	AN IN VITRO METHOD FOR HIGH THROUGHPUT SCREENING OF GENOTOXIC AGENTS IN EUKARYOTIC CELLS	EP	Granted	EP12768664A	7-Apr-2012	7-Apr-2032	
2.	Acid (5-substituted oxy-2, 4-dinitro-phenyl) -2-oxo-propionic acid ester compounds, process and applications thereof	Spain	Granted	ES20140733718T	5-Jun-2014	5-Jun-2034	
3.	COMPOUNDS OF '3-(5-SUBSTITUTED OXY-2,4-DINITRO-PHENYL)-2-OXO-PROPIONIC ACID ESTER', PROCESS AND APPLICATIONS THEREOF	EP	Granted	EP14733718A	5-Jun-2014	5-Jun-2034	
4.	ACID ESTER COMPOUNDS 3- (5-REPLACED OXY-2,4-DINITROPHENYL) -2- OXO-PROPYLIC, PROCESS AND APPLICATIONS OF THE SAME	Brazil	Granted	BR112015030527A	5-Jun-2014	5-Jun-2034	
5.	COMPOUNDS OF '3-(5-SUSTITUTED OXY-2,4-DINITRO-PHENYL)-2-OXO-PROPIONIC ACID ESTER', PROCESS AND APPLICATIONS THEREOF	Republic of Korea	Granted	KR20167000247	5-Jun-2014	5-Jun-2034	



S MAJUMDAR & CO

Advocates, Patent & Trademark Attorneys

Kolkata | New Delhi | Mumbai

www.majumdarip.com

6.	AN IN VITRO METIOD FOR HIGH THROUGHPUT SCREENING OF GENOTOXIC AGENTS IN EUKARYOTIC CELLS	Hong Kong	Granted	HK20140107711	29-Jul-2014	29-Jul-2034	
7.	NOVEL EXPRESSION AND SECRETION VECTOR SYSTEMS FOR HETEROLOGOUS PROTEIN PRODUCTION IN ESCHERICHIA COLI	Hong Kong	Granted	HK20140107855	31-Jul-2014	31-Jul-2034	
8.	COMPOUNDS OF '3-(5-SUBSTITUTED OXY-2,4-DINITRO-PHENYL)-2-OXO-PROPIONIC ACID ESTER', PROCESS AND APPLICATIONS THEREOF	South Africa	Applied	ZA20150008750	30-Nov-2015	30-Nov-2035	
9.	SYNTHESIS OF A GUANYLATE CYCLASE AGONIST BY FRAGMENTS BASED APPROACH	United States of America	Applied	US202118009652A	15-Jun-2021	15-Jun-2041	
10.	Method for producing glycolipid carboxylic acids	Republic of Korea	Applied	KR20247002545A	24-Jun-2022	24-Jun-2042	
11.	Preparation method of glycolipid carboxylic acid	China	Applied	CN202280044457A	24-Jun-2022	24-Jun-2042	
12.	A METHOD FOR PREPARATION OF GLYCOLIPID CARBOXYLIC ACIDS	EP	Applied	EP22827822A	24-Jun-2022	24-Jun-2042	
13.	A METHOD FOR PREPARATION OF GLYCOLIPID CARBOXYLIC ACIDS	Australia	Applied	AU2022297739A	24-Jun-2022	24-Jun-2042	
14.	A METHOD FOR PREPARING GLYCOLIPIDI CARBOXYLIC ACIDS	Brazil	Applied	BR112023026771A	24-Jun-2022	24-Jun-2042	
15.	A Method for Preparation of Glycolipid Carboxylic Acids	United States of America	Applied	US202218574060A	24-Jun-2022	24-Jun-2042	
16.	Method for producing	Japan	Applied	JP2023579543A	24-Jun-2022	24-Jun-	



S MAJUMDAR & CO

Advocates, Patent & Trademark Attorneys

Kolkata | New Delhi | Mumbai

www.majumdarip.com

	glycolipid carboxylic acid					2042	
17.	A Method for Preparation of Glycolipid Carboxylic Acids	Hong Kong	Applied	62024092213.3	24-Jun-2022	24-Jun-2042	